Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
• Potentially Resectable NSCLC
• Treatment Plan is Crizotinb or Standard Chemotherapy
Locations
Other Locations
China
Yongchang Zhang
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Nong Yang, MD
yangnong0217@163.com
+8613055193557
Time Frame
Start Date: 2020-03-24
Estimated Completion Date: 2025-03-24
Participants
Target number of participants: 70
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital